

02 September 2025

## **Patients Diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)**

**Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?**

Within BHSCT we can confirm 12 patients were diagnosed with Diffuse Large B Cell Lymphoma (DLBCL) in the last 6 months

**Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months?**

Within BHSCT we can confirm 12 patients were treated with Diffuse Large B Cell Lymphoma (DLBCL) in the last 6 months

**Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:**

Belfast Trust does not hold this information centrally as electronic prescribing is not in place for haematology. To retrieve it would require a manual trawl of individual patient records, which would take more than 18 hours.

- **R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)**
- **R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)**
- **Pola-BR (polatuzumab vedotin with rituximab and bendamustine)**
- **Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)**
- **R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)**
- **R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)**
- **R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone)**
- **(DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab)**
- **R-GemOX (rituximab, gemcitabine and oxaliplatin)**
- **Axicabtagene ciloleucel**
- **Tisagenlecleucel**
- **Epcoritamab**
- **Loncastuximab tesirine**
- **Glofitamab**

**02 September 2025**

- **Any other SACT**
- **Stem cell transplant or bone marrow transplant (autologous or allogeneic)**

**Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):**

Belfast Trust does not hold this information centrally as electronic prescribing is not in place for haematology. To retrieve it would require a manual trawl of individual patient records, which would take more than 18 hours.

- **Axicabtagene ciloleucel (Yescarta)**
- **Tisagenlecleucel**
- **Pola-BR (polatuzumab vedotin with rituximab and bendamustine)**
- **R-GemOX (rituximab, gemcitabine and oxaliplatin)**
- **Stem cell transplant or bone marrow transplant (autologous or allogeneic)**
- **Any other treatments**

**Q4. In the last 6 months, how many patients has the Trust treated for 3rd line Diffuse Large B Cell Lymphoma (DLBCL)?**

Belfast Trust does not hold this information centrally as electronic prescribing is not in place for haematology. To retrieve it would require a manual trawl of individual patient records, which would take more than 18 hours

**Q5. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:**

<5 for Matched Unrelated Donor Transplant

Where numbers are low we have indicated <5 rather than give the exact figure. We feel that providing the exact figure has the potential to make people identifiable and so that information is exempt from release under Section 40(2) of the Freedom of Information Act 2000.

- **CAR-T Therapy (E.g. Axicabtagene ciloleucel)**
- **Stem cell transplant or bone marrow transplant (autologous or allogeneic)**
- **Any other treatment**

Belfast Trust does not hold this information centrally as electronic prescribing is not in place for haematology. To retrieve it would require a manual trawl of individual patient records, which would take more than 18 hours

Belfast Trust considers that the cost of retrieving the information would be above the 'Appropriate Limit', as defined by the Freedom of Information Act under Section 12. Section 12 of the Freedom of Information Act makes provision for public authorities to refuse requests for information where the cost of dealing with them

**02 September 2025**

would exceed the appropriate limit. The limit has been specified as £450 for public authorities such as Belfast Trust. This represents the cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.